問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taichung Veterans General Hospital

List

1449Cases

2019-03-01 - 2023-12-31

Phase III

A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy

  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    Cabozantinib (XL184) 20mg and 60mg tablet; Atezolizumab 1200mg/ 20ml solution for IV infusion

Participate Sites
9Sites

Recruiting7Sites

Terminated2Sites

2019-05-01 - 2023-05-02

Phase II

A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)

  • Condition/Disease

    Head and Neck Squamous Cell Carcinoma (HNSCC)

  • Test Drug

    Tipifarnib

Participate Sites
8Sites

Recruiting6Sites

Terminated2Sites

2019-07-01 - 2021-11-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting3Sites

Terminated3Sites

2014-09-01 - 2019-11-30

Phase II

TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO 1686 as 2nd Line EGFR-Directed TKI in Patients with Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) with the T790M Resistance Mutation

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    CO-1686 Hydrobromide Film-Coated Tablets

Participate Sites
5Sites

Terminated5Sites

2015-05-01 - 2018-12-31

Phase II

A single blind, randomised, multi-centre, active controlled, trial to evaluate safety, tolerability, pharmacokinetics and efficacy of ceftazidime and avibactam compared with cefepime in children from 3 months to less than 18 years of age with complicated urinary tract infections (cUTIs)

  • Condition/Disease

    Complicated urinary tract infections (cUTIs)

  • Test Drug

    Ceftazidime Avibactam powder for concentrate for solution for infusion 2000 mg / 500 mg

Participate Sites
5Sites

Terminated3Sites

Study ended1Sites

2015-09-09 - 2017-11-30

Phase III

TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non-small Cell Lung Cancer (NSCLC) after Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinumdoublet Chemotherapy

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    CO-1686 Hydrobromide Film-Coated Tablet

Participate Sites
6Sites

Terminated5Sites

夏德椿
China Medical University Hospital-Taipei

未分科

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

2016-02-01 - 2017-12-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2015-09-01 - 2018-03-31

Phase II

A phase 2, parallel group, to explore the study of MGCD265 in patients with locally advanced or metastatic non-small cell lung cancer with active gene mutations in mesenchymal-epithelial transforming factor

  • Condition/Disease

    NSCLC

  • Test Drug

    MGCD265

Participate Sites
6Sites

Terminated6Sites

2016-08-01 - 2018-12-31

Phase III

A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

  • Condition/Disease

    carbapenem-resistant Gram-negative bacterial infections

  • Test Drug

    S-649266

Participate Sites
7Sites

Terminated7Sites

2017-03-14 - 2020-11-01

Phase III

A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer

  • Condition/Disease

    ALK-positive advanced lung cancer

  • Test Drug

    Brigatinib (AP26113)

Participate Sites
6Sites

Recruiting5Sites

夏德椿
China Medical University Hospital-Taipei

未分科

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

1 109 110 111 112 113 145
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB